Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 10, Issue 1, Pages 7-18Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2014.861325
Keywords
anakinra; auto-inflammatory diseases; canakinumab; chronic infantile neurological cutaneous and articular syndrome; cryopyrin-associated periodic syndrome; familial cold urticaria; familial cold auto-inflammatory syndrome; IL-1; Muckle-Wells syndrome; neonatal-onset multisystem inflammatory disease; rilonacept; treatment
Categories
Funding
- Novartis Pharma
- Pfizer
- Abbott
- Chugai
- SOBI Biovitrum
- Novartis
Ask authors/readers for more resources
Cryopyrin-associated periodic syndrome (CAPS) is a very rare auto-inflammatory syndrome, which has recently served as a pure model of IL-1 beta-driven diseases. CAPS is caused by mutations into the NLRP3 gene that encodes crypoyrin, which serves as a receptor of the innate immunity that senses danger signals and pathogens. Constitutive activation of cryopyrin in CAPS leads to an excessive secretion of IL-1 beta. CAPS patients experience symptoms of systemic inflammation, intense fatigue and have poor quality of life. In the most severe forms, they may develop serious organ damage such as visual and hearing impairment, neurological deterioration and renal insufficiency. Anti-IL-1 drugs are effective in treating symptoms of almost all CAPS patients and have radically transformed their lives. We describe the history of the 'revival' of CAPS patients through anti-IL-1 treatments with a special focus on anakinra, the first drug used in cohorts with variable disease severity and number of patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available